French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) confirmed on Friday that it has completed its acquisition of Blueprint Medicines Corporation (NASDAQ:BPMC).

This enhances Sanofi's rare disease and immunology portfolio with the addition of a marketed therapy, an advanced pipeline, and specialized expertise in systemic mastocytosis and KIT-driven diseases.

The acquisition includes Ayvakit (avapritinib), the only approved treatment for both advanced and indolent systemic mastocytosis in the United States and European Union. Sanofi also gains elenestinib, currently in a phase 2/3 trial for indolent and smoldering systemic mastocytosis, and BLU-808, an investigational wild-type KIT inhibitor targeting broader inflammatory conditions.

Through the deal, Sanofi strengthens its relationships with allergists, dermatologists, and immunologists, which is expected to support its expanding immunology pipeline. The acquisition was completed via a tender offer followed by a merger, with Blueprint now operating as an indirect, wholly owned subsidiary of Sanofi.

Sanofi is financing the transaction with cash on hand and commercial paper, with no material impact expected on its 2025 financial guidance. The acquisition is immediately accretive to gross margin and is expected to be accretive to business operating income and earnings per share after 2026.

Shareholders who did not tender their Blueprint shares will receive USD129.00 per share in cash, plus contingent rights of up to USD6.00 per share based on future milestones. Blueprint common stock will no longer trade on the NASDAQ Global Select Market as of 18 July 2025.